VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-6.61%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$670M
AUM Growth
+$108M
(+19%)
Cap. Flow
+$134M
Cap. Flow
% of AUM
20%
Top 10 Holdings %
Top 10 Hldgs %
59.41%
Holding
183
New
13
Increased
76
Reduced
55
Closed
39
Top Buys
| 1 |
ETP
Energy Transfer Partners, L.P.
ETP
|
$65.6M |
| 2 |
WPZ
Williams Partners L.P.
WPZ
|
$17.9M |
| 3 |
BPL
Buckeye Partners, L.P.
BPL
|
$14.6M |
| 4 |
Enterprise Products Partners
EPD
|
$13.8M |
| 5 |
Energy Transfer Partners
ET
|
$13.8M |
Top Sells
| 1 |
ETP
Energy Transfer Partners L.p.
ETP
|
$45.5M |
| 2 |
iShares Short Treasury Bond ETF
SHV
|
$34.1M |
| 3 |
Marathon Petroleum
MPC
|
$6.21M |
| 4 |
SPDR S&P 500 ETF Trust
SPY
|
$4.73M |
| 5 |
ProShares Ultra S&P500
SSO
|
$4.67M |
Sector Composition
| 1 | Energy | 73.91% |
| 2 | Healthcare | 7.71% |
| 3 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Insmed
INSM
$30B
| $324K | 0.05% |
18,896
-2,986
| -14% | -$51.2K |
|
|
ACHN
102
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $323K | 0.05% |
70,350
+900
| +1% | +$4.13K |
|
103
Novavax
NVAX
$1.26B
| $322K | 0.05% |
14,004
+3,156
| +29% | +$72.6K |
|
|
PRTK
104
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $322K | 0.05% |
13,379
-6,830
| -34% | -$164K |
|
|
ARRY
105
DELISTED
Array Biopharma Inc
ARRY
| $321K | 0.05% |
38,373
+6,350
| +20% | +$53.1K |
|
|
LOXO
106
DELISTED
Loxo Oncology, Inc
LOXO
| $321K | 0.05% |
4,009
-6,399
| -61% | -$512K |
|
107
Alnylam Pharmaceuticals
ALNY
$59.2B
| $320K | 0.05% |
4,007
-2,471
| -38% | -$197K |
|
108
Corbus Pharmaceuticals
CRBP
$123M
| $320K | 0.05% |
1,693
+608
| +56% | +$115K |
|
|
LJPC
109
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $320K | 0.05% |
10,761
-5,087
| -32% | -$151K |
|
|
KDNY
110
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $318K | 0.05% |
5,576
+464
| +9% | +$26.5K |
|
|
ARAV
111
DELISTED
Aravive, Inc. Common Stock
ARAV
| $317K | 0.05% |
+3,027
| New | +$317K |
|
112
Geron
GERN
$887M
| $316K | 0.05% |
113,952
-23,243
| -17% | -$64.5K |
|
|
CALA
113
DELISTED
Calithera Biosciences, Inc
CALA
| $315K | 0.05% |
+1,059
| New | +$315K |
|
114
Celldex Therapeutics
CLDX
$1.5B
| $314K | 0.05% |
8,466
+3,450
| +69% | +$128K |
|
115
Rigel Pharmaceuticals
RIGL
$716M
| $313K | 0.05% |
11,483
+243
| +2% | +$6.62K |
|
116
Regenxbio
RGNX
$470M
| $310K | 0.05% |
+15,691
| New | +$310K |
|
|
SAGE
117
DELISTED
Sage Therapeutics
SAGE
| $306K | 0.05% |
3,846
-1,991
| -34% | -$158K |
|
118
Neurogene
NGNE
$283M
| $305K | 0.05% |
1,084
+180
| +20% | +$50.6K |
|
119
Xencor
XNCR
$603M
| $305K | 0.05% |
14,429
+3,079
| +27% | +$65.1K |
|
|
XLRN
120
DELISTED
Acceleron Pharma Inc.
XLRN
| $303K | 0.05% |
9,973
+272
| +3% | +$8.26K |
|
121
Ultragenyx Pharmaceutical
RARE
$3.01B
| $302K | 0.05% |
4,855
+883
| +22% | +$54.9K |
|
122
Agios Pharmaceuticals
AGIO
$2.06B
| $301K | 0.04% |
5,847
+578
| +11% | +$29.8K |
|
123
Akebia Therapeutics
AKBA
$806M
| $301K | 0.04% |
+20,913
| New | +$301K |
|
|
FPRX
124
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $300K | 0.04% |
9,963
+4,335
| +77% | +$131K |
|
|
SIOX
125
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $298K | 0.04% |
1,607
-1,181
| -42% | -$219K |
|